Completed PHASE2 INTERVENTIONAL 1-arm NCT00404495

Combination of Irinotecan and Temozolomide in Children With Brain Tumors.

Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.

Sponsor: Pfizer

Conditions Glioma Medulloblastoma

Interventions Irinotecan Temozolomide

Updated 8 times since 2017 Last updated: Apr 16, 2012 Started: Apr 30, 2007 Primary completion: Jan 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00404495, this PHASE2 trial focuses on Glioma and Medulloblastoma and remains completed. Sponsored by Pfizer, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus N, Denmark , Angers, France , Barcelona, Spain , Birmingham, United Kingdom , Bordeaux, France , El Palmar, Spain , Esplugues de Llobregat, Spain , Ghent, Belgium , Herston, Australia , Koebenhavn OE, Denmark and 19 more locations